Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of the Device Nit-Occlud® PDA-R

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical and echocardiographic compatibility with PDA without associated heart disease requiring surgical solution~* Minimum diameter of the PDA 2 to 8 mm~* Systolic pulmonary pressure measured during cardiac catheterization, not on pass 2/3 of the values of the systolic systemic pressure~* Weight higher than 10 kg, regardless of age~* Patients who were diagnosed and recruited during the period 2009 - 2010~* Patients with trisomy 21 also fulfill the previous criteria, the number of patients with T21 will not exceed 10% of the entire group of patients.~* letter of consent signed by parents or legal guardian~Relative Exclusion Criteria:~* Infections that occur during acute bacteremia, viremia, which can be treated~* Febrile syndrome~* Tooth decay~* Once the acute solved considering the patient's inclusion into the study~Exclusion Criteria:~* Pregnant women~* Pulmonary hypertension, increased to 2 / 3 of systemic pressure~* Eisenmenger syndrome~* Other associated heart disease, requiring surgical solution~* Immuno-compromised patients~* Pathology oncology~* Hematologic or coagulation disorders~* Allergy to contrast medium~* Atypical or calcified Ductus~* Parents or legal guardians who do not accept the risks of catheterization~* Parents or legal guardians and patients who do not accept to sign the letter of consent or who revoke the consent.~* Patients who participated in another clinical investigation during the last 3 months

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nit-Occlud PDA-R (Type: OTHER): Interventional, prospective clinical study, non randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).